volociximab   Click here for help

GtoPdb Ligand ID: 10236

Synonyms: M200
Compound class: Antibody
Comment: Volociximab is a chimeric human IgG4 anti-integrin α5 subunit monoclonal antibody [5]. It blocks the interaction between α5β1 and fibronectin and inhibits the complex's functional activity [4], and was originally developed for anti-angiogenic, anti-tumour potential [1-2]. Volociximab does not cross-react with murine α5β1 so is unsuitable for use in standard xenograft models [2]. A rat anti-mouse function-blocking α5β1 designed for murine experiments has been reported (339.1, Kd 0.59 nM), and like volociximab it inhibits angiogenesis and slows tumour growth in vivo[3].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Development of volociximab for the treatment of solid tumours was terminated at Phase 2 due to a lack of observed clinical activity. Click here to link to ClinicalTrials.gov's full list of volociximab trials.